title: [Biological treatment of refractory Crohn's disease: three years of observation].
authors.forename: L B
authors.initials: LB
authors.lastname: Lazebnik
authors.forename: O V
authors.initials: OV
authors.lastname: Kniazev
authors.forename: A I
authors.initials: AI
authors.lastname: Parfenov
authors.forename: A G
authors.initials: AG
authors.lastname: Konopliannikov
authors.forename: V E
authors.initials: VE
authors.lastname: Sagynbaeva
authors.forename: I N
authors.initials: IN
authors.lastname: Ruchkina
authors.forename: R B
authors.initials: RB
authors.lastname: Gudkova
authors.forename: S G
authors.initials: SG
authors.lastname: Khomeriki
authors.forename: B Z
authors.initials: BZ
authors.lastname: Chikunova
authors.forename: Z F
authors.initials: ZF
authors.lastname: Mikhaĭlova
authors.forename: P L
authors.initials: PL
authors.lastname: Shcherbakov
authors.forename: V A
authors.initials: VA
authors.lastname: Rogozina
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003424:Crohn Disease / Q000188:drug therapy* / Q000601:surgery*; D005260:Female; D006801:Humans; D000069285:Infliximab; D053208:Kaplan-Meier Estimate; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D008875:Middle Aged; D055502:Secondary Prevention; D012720:Severity of Illness Index; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab